Biotechnology
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available inEurope for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) ha...
2024-09-21 13:42
4371
European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare
KOTA KINABALU, Malaysia, Sept. 21, 2024 /PRNewswire/ -- European Wellness, a global leader in regenerative medicine and integrated healthcare, has inaugurated its latest and most advanced facility, the European Wellness New Premier Center, in Kota Kinabalu,Sabah. This landmark 60,000 square-foot ...
2024-09-21 09:00
4966
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting
BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...
2024-09-20 20:30
1485
Kangpu Completed Bridging Clinical Study of KPG-818 in China
HEFEI, China, Sept. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inHefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects inChina. The randomized, double-blind, placebo-controlled,...
2024-09-20 20:00
2003
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
SUZHOU, China, Sept. 20, 2024 /PRNewswire/ -- CD (Suzhou) Biopharma
2024-09-20 16:28
1597
Frost & Sullivan grants the Global Cognitive Impairment Digital Therapy Innovation Award to BRAINAU
SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held inShanghai from August 27 to 30, 2024 , co-hosted by LeadLeo. Based on research and analysis of the global...
2024-09-19 21:48
2204
Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024
BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...
2024-09-19 20:30
1104
Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, tod...
2024-09-19 17:28
2175
Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculture
Amid rising agricultural complexity and the push for sustainability, genomics is at the forefront of innovation in breeding practices. SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomic...
2024-09-19 14:00
10469
MGI Tech partners with Dasa to enhance health diagnosis with genetic sequencing in Brazil
New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country SÃO PAULO, Brazil, Sept. 18, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building ...
2024-09-19 11:05
1265
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...
2024-09-19 09:00
4419
Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024
Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), ...
2024-09-19 08:00
4349
Watson-Marlow unveils Qdos™ H-FLO and WMArchitectTM :Innovating fluid solutions for the chemical and biopharmaceutical industries respectively
SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Watson-Marlow Fluid Technology
Solutions (WMFTS), a world leader in manufacturing peristaltic pump and
associated fluid path technologies for process industries and life sciences,
has announced the launch ofQdos™ H-FLO
2024-09-19 08:00
12626
Zymo Research Stands by Its Innovative cfDNA Technology in Response to Qiagen's Lawsuit
IRVINE, Calif., Sept. 18, 2024 /PRNewswire/ -- Zymo Research Corporation, a leader in innovative life science solutions, acknowledges the patent infringement lawsuit filed by Qiagen GmbH onAugust 20, 2024, at the US District Court for the Central District ofCalifornia regarding its MAGicBead cfDN...
2024-09-18 22:00
1289
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
* ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. * Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dos...
2024-09-18 21:30
1095
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and rese...
2024-09-18 18:18
1483
Frost & Sullivan grants the Global Medical Imaging Foundation Model Innovation Award to Hangzhou Diagens Biotechnology Co.,Ltd.
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held inShanghai from August 27 to 30, 2024 , co-hosted by LeadLeo. Based on the research and analysis of the gl...
2024-09-18 16:16
1538
Clarivate Announces 15th Annual Pharmavision India Conference Agenda
Industry leaders to discuss AI in healthcare, cell and gene therapy, market access and more at premier life sciences event LONDON, Sept. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 15th annua...
2024-09-18 15:00
1785
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with theUniversity of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters,...
2024-09-18 09:26
1343
BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr.Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life scien...
2024-09-18 08:30
1313
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 305 media titles]
2024-12-27 13:17
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 253 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 245 media titles]
2024-12-25 15:45Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
[Picked up by 239 media titles]
2024-12-27 11:24
